Latest Commercialization News

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Axel REE has selected its Woolrich deposit for inaugural in situ recovery (ISR) field trials, backed by metallurgical breakthroughs doubling gallium extraction and confirming scandium co-recovery, positioning Caladão as a rare dual-pathway rare earth project.

HyTerra Ltd is progressing its flagship Nemaha hydrogen project with a key production test planned for Q2 2026, while expanding its global footprint through strategic partnerships and a $7 million capital raise.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Omega Oil and Gas has secured a commanding acreage position in Queensland’s Taroom Trough and fully funded an expanded drilling program to accelerate appraisal and early production.

Mont Royal Resources is on track to release an updated Preliminary Economic Assessment for its Ashram Rare Earths project in May, with a promising geological review highlighting the BD-Zone as a key area for resource expansion. The company also secured a strategic non-binding MOU with Saguenay Port Authority and extended funding for critical infrastructure.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

Metal Powder Works has scaled its NextGen powder production to 100 metric tonnes per annum with an industry-leading saleable yield above 95%, setting the stage for an 800MT capacity by 2028 at a fraction of conventional costs.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.